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We have developed a novel fragile X locus repeat
assay that is a simple and high-throughput method
that, with clinical validation, may be suitable for
screening. It uses amplification of the FMR1 trinucle-
otide repeat region, followed by a hybridization assay
to quantify the number of repeats in the amplicons.
To our knowledge, this is the first repeat-counting
assay that uses fluorescent signals rather than elec-
trophoresis or mass spectrometry as the signaling
mechanism. We also report the development of a sim-
ple microfluidic electrophoresis reflex test that uses
the same amplicons and reduces the need for South-
ern blots to differentiate homozygous female normal
samples from full mutations. The new assay, which is
based on a suspension-array hybridization method,
was tested on a series of male and female reference
samples spanning the range from normal to full mu-
tations. It was also tested on DNA from 1008 dried
blood spot samples from pregnant women in their
first trimester. The hybridization assay identified 51
of those as potentially expanded alleles of >45 re-
peats or as intermediate or higher in FMR1 repeat
classification. Of these screen-positive samples, eight
were confirmed by microfluidic electrophoresis as
premutations consisting of >55 repeats. The FMR1
repeat assay is straightforward to run in high
throughput, and the results are in the form of numer-
ical ratios for ease of initial interpretation. (J Mol
Diagn 2011, 13:614–620; DOI: 10.1016/j.jmoldx.2011.06.002)
Expansion of the CGG trinucleotide repeat region of the
FMR1 gene is the cause of a range of debilitating disor-
ders.1 Fragile X syndrome, caused by the methylation
and silencing of the gene when the CGG repeat motif
614expands 200 repeats (a full mutation), is the most fre-
quent inherited cause of mental retardation. Individuals
with smaller repeat expansions in the premutation range
of 55 to 200 repeats may be affected with other syn-
dromes or conditions. Middle-aged males with premuta-
tions may develop fragile X–associated tremor/ataxia
syndrome, a neurodegenerative disorder.2–7 Women car-
rying the premutation have an elevated risk of developing
premature ovarian failure8–12 and thyroid disease and
muscle pain.13 The fragile X premutation state has more
recently been associated with cognitive deficits, behav-
ioral problems, and autism spectrum disorders.14–20 As
research into the phenotypic effects of both full mutations
and premutations refines the understanding of their se-
verity and prevalence, there arises the need for testing or
screening for these conditions in a wider number of clin-
ical settings.21–23 This, in turn, highlights the need for
higher throughput and simpler tests for assessing the
number of CGG repeats at this locus.
Much of fragile X repeat testing has been performed
by FMR1-specific PCR, followed by capillary electropho-
resis on a sequencing instrument. Differentiating full mu-
tations from homozygous (or nearly homozygous) normal
female samples and confirming full mutations in males
have required either a Southern blot reflex test or, more
recently, interpretation of stutter electropherograms from
repeat-primed PCR products24–26 (see also the Ameri-
can College of Medical Genetics Technical Standard
and Guideline for Fragile X Testing, http://www.acmg.net/
Pages/ACMG_Activities/stds-2002/fx.htm, last accessed
January 2011). Southern blots are labor intensive and
take multiple days to complete; interpretation of the stut-
ter electropherograms requires visual evaluation by a
skilled practitioner, and capillary sequencing instruments
are still relatively expensive to obtain and maintain.
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mutation status in prospective mothers, has not been
widely adopted because of the complexity and cost of
the available assay technologies.22,27 Furthermore, most
laboratory-developed tests using PCR and capillary elec-
trophoresis with reflexing to Southern blots have pro-
duced inconsistent results on reference samples.28 The
purpose of this study was to perform a preliminary tech-
nology evaluation of a new type of FMR1 assay method to
determine whether such an approach could be a practi-
cal candidate for maternal carrier screening, thus de-
creasing the need for Southern blot reflex testing.
Although there is not complete consensus in the liter-
ature,29 fragile X premutations, as used herein, are de-
fined as expanded alleles of between 55 and 200 re-
peats. The risk of transmitting a full mutation from a
mother to the next generation increases with the size of
the premutation up to approximately 100 repeats, the
point at which the risk of a full mutation in offspring
reaches approximately 100%. The full mutation transmis-
sion risk versus maternal carrier premutation allele size
was summarized by Nolin et al.30
The shortest maternal premutation that has transmitted
a full mutation to the next generation is 5930; however, the
guidelines define the premutation state as having a lower
boundary of 55 as a conservative value. Thus, a maternal
carrier testing or screening strategy could be to first test
samples to determine whether the allele size is55 using
a simple high-throughput assay, then to reflex test the
samples with positive results for a more precise assess-
ment of the repeat number to determine an individual
patient’s risk of full mutation transmission. For a screen-
ing assay, the cutoff for the initial test would be set at55
so that the risk of a screen false-negative result would be
minimized. For example, the prevalence of premutation in
women in various populations was measured as 1
(0.56%) of 178 in the United States in 20101,31 and as 1
(0.64%) of 157 in Israel in 2007.32 Accordingly, the num-
ber of screen-positive results reflexed to a diagnostic test
would be expected to be in the low single-digit percent-
age range.
The novel assay described herein has the attributes
needed for widespread carrier screening: low labor input,
results on the same day, high throughput, and numerical
results for ease of interpretation.
Materials and Methods
Samples
To demonstrate general assay performance, a collection
of reference samples from the Coriell Research Institute
(Trenton, NJ) with a known range of repeat numbers,
including full mutations, was first evaluated. These sam-
ples were provided in the form of genomic DNA, and no
extraction or purification was required. The female refer-
ence samples were Coriell NA 07542, 20236, 06905,
06907, 20241, 20239, 07537, and 05847 and American
Type Culture Collection (ATCC) CRL-2704D. The malereference samples were Coriell NA 07539, 20230, 20231,
06892, 20237, 06852, 06897, and 04025.
After characterizing the assay’s performance with ref-
erence samples, we tested DNA from 1008 de-identified
dried blood spot (DBS) specimens from pregnant women
(left over from first-trimester aneuploidy risk screening) to
evaluate the assay’s technical performance on clinical
samples. No patients or samples were recruited for this
study, and no results were reported back to patients or
physicians. This study (no. 11-013) was reviewed and
approved by the New England Institutional Review Board
(Newton, MA). In addition, a waiver of informed consent
for use of the samples in the study was approved by the
New England Institutional Review Board.
DBS cards have been the standard sample carrier for
newborn screening for many years and have been used
in pilot studies for FMR1 testing for newborn screen-
ing.33,34 More recently, DBS samples are being adopted in
first- and second-trimester maternal aneuploidy risk screen-
ing to take advantage of their low cost, ease of transport,
and stabilization of blood analytes.35,36 The DBS sample
format was chosen for this assay technology study because
of its relevance to the maternal FMR1 premutation screen-
ing setting. For each sample, three 3.2-mm diameter
punches from a blood spot card were placed in a well of a
1.2-mL deep-well microplate. DNA was extracted using the
QIAmp DNA Micro kit (Qiagen, Valencia, CA), according to
the kit insert protocol, and eluted in 20 L.
PCR of the FMR1 Repeat Region
The FMR1 repeat region of each sample was amplified using
PCR. Forward and reverse primers were prepared to straddle
the CGG repeat region, amplifying the repeat region plus 239
additional flanking bases upstream and downstream of the
repeats. The primer sequences were from the literature24: 5=-
TCAGGCGCTCAGCTCCGTTTCGGTTTCA-3= (forward) and
5=-FAM-AAGCGCCATTGGAGCCCCGCACTTCC-3=
(reverse) (Integrated DNA Technologies, Coralville, IA). An
aliquot of the purified blood spot DNA eluate (4 L) was used
as the template and amplified on a thermal cycler (Tetrad 2;
Bio-Rad, Hercules, CA). There was an initial denaturation step
of 95°C for 5 minutes; followed by 25 cycles of 98°C for 35
seconds, 62°C for 35 seconds, and 72°C for 4 minutes; and a
final extension step of 72°C for 10 minutes.
The total PCR time was less than 2.5 hours. The PCR
reagent formulations were PerkinElmer (Waltham, MA) pro-
prietary. The reverse primer was end labeled with FAM,
which facilitated two functions. First, FAM is one of the
labels detected by the Applied Biosystems (Foster City, CA)
and other capillary electrophoresis sequencers, which are
the main detection platforms used for most of today’s fragile
X assays. This allows the length of PCR products made by
this protocol to be evaluated by the capillary sequencers
used for conventional fragile X testing, if desired. Second,
FAM is a hapten that is a specific binding partner to fluo-
rescein-specific antibodies. The FAM molecule was de-
tected by an anti-fluorescein-phycoerythrin reporter that
was, in turn, quantified by the suspension array platform
used in the new hybridization method.
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labeled with biotin. Thus, these labeled nucleotides were
incorporated into the PCR products and, in particular,
were incorporated into the CGG repeat portion of the
molecules in approximate proportion to the repeat length.
The biotin labels were later detected by a second fluo-
rescent reporter, streptavidin-phycoerythrin, in the hy-
bridization assay described later.
Hybridization Assay and Analysis
Each sample’s PCR product, 1 L, was used as the input to
the fluorescence hybridization assay and was mixed with
hybridization buffer and the suspension array bead mix in a
well of a 96-well PCR plate. Oligonucleotide capture probes
(21 bases, 7  CGG  5= amino) coupled to the beads by
the standard 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide protocol enabled hybridization capture of the reverse-
strand PCR products, which have a GCC trinucleotide re-
peat motif. The reverse strand was chosen for capture
because it has more Cs in the repeat region (and, thus, a
higher density of the incorporated biotin labels) and be-
cause it has the FAM-labeled primer. The mixture of PCR
Figure 1. Results of the hybridization assay and demonstration of microflui
assay response curve for the eight female reference samples. B: The response
for three of the female references (normal, near the premutation cutoff, and a large f
references of similar repeat lengths (D, NA 07539; F, NA 20230; and H, NA 04025).products, beads, and hybridization buffer was denatured
for 5 minutes at 100°C and then hybridized at 65°C
while shaking at 1200 rpm and 3mm diameter orbit
(24xg) in a TriNEST microplate incubator (PerkinElmer,
Turku, Finland) for 1 hour. After hybridization, the wash
buffer comprising 1 PBS and 0.01% Tween 20
(Sigma-Aldrich, St. Louis, MO) was added to each well. The
beads were then washed twice more with the same buf-
fer, and two aliquots of each sample’s hybridized beads
were transferred into two wells of a Multiscreen HTS
0.45-m filter plate (Millipore, Bedford, MA).
The beads were split into two aliquots in different wells of
a filter plate for the application of two different fluoresc-
ent reporters. The streptavidin-phycoerythrin reporter
(ProZyme, Hayward, CA) was diluted 1:250 in 1 PBS with
0.1% bovine serum albumin and 0.01% Tween 20. The
diluted reporter was applied to, and incubated with, one set
of hybridized beads; a similarly diluted anti-fluorescein-phy-
coerythrin reporter (Invitrogen, Carlsbad, CA) was applied
to, and incubated with, the other set for 10 minutes at room
temperature, with shaking. After a final wash, beads were
resuspended and the fluorescent signals were read on the
Luminex 200 suspension array system (Luminex Corp, Aus-
trophoresis confirmation with panels of reference samples. A: Hybridization
r the eight male reference samples. C–H:Microfluidic electrophoresis resultsdic elec
curve foull mutation) (C, NA 07540; E, CRL-2704D; and G, NA 05847) and three male
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a single operator analyzing 48 samples in a run.
The streptavidin-phycoerythrin fluorescence signal (gen-
erated from the biotinylated nucleotides) would be ex-
pected to be proportional to the number of C nucleotides,
hence the CGG repeat length, in each PCR product mole-
cule. The anti-fluorescein-phycoerythrin fluorescence signal
(from the FAM on each reverse primer) is proportional to the
number of PCR product molecules produced in a particular
PCR, which varies considerably from sample to sample.
The ratio of the two signals is a representation of the CGG
repeat length of a sample:
Incorporated Biotin Label Signal ⁄ Primer FAM
Label Signal  Number of CGG Repeats ⁄
PCR Product Molecule
For the DBS sample assay runs, four female reference
samples with known repeat lengths were run alongside
each batch through PCR and hybridization: Coriell NA
07540 (23 and 29 repeats, respectively), Coriell NA
20238 (29 and 30 repeats, respectively), ATCC
CRL2704D (31 and 59 repeats, respectively), and Coriell
NA 20239 (20 and 200 repeats, respectively). Samples
were run in batches of 48, comprising 44 samples to be
characterized along with four standards. A standard
curve was constructed from the fluorescence ratios gen-
erated by the four standards, using the longer allele of
each female standard as that reference sample’s char-
acteristic repeat length, and a second-order polynomial
curve was fit to the four points. This standard curve was
then used to calculate the repeat length of the longer
allele of each of the unknown samples in the run.
Reflex Testing and Confirmation with
Microfluidic Electrophoresis
Samples identified as potentially expanded by the hy-
bridization assay were reflex tested by capillary elec-
trophoresis of the PCR products. It is common practice
with screening assays to identify a screening cutoff
Table 1. Blood Spot Hybridization Assay Results Summary
Variable Value
No. of samples 1008
No. of results 997






55 by hybridization assay:
screen positives
No. 17
% (number/total) 1.71 (17/995 or 1/59)
55 confirmed by electrophoresis
No. 8
% (number/total) 0.80 (8/995 or 1/125)that minimizes the possibility of false-negative results(undetected premutations in this case) at the expense
of producing more screen-positive results that need to
be reflexed. An empirically determined initial screen
cutoff of 45 repeats, as measured by the hybridiza-
tion assay, was used to initiate reflex testing in this
study. No premutations were found in any of the sam-
ples assessed at 48 repeats or lower by the hybridiza-
tion assay.
Reflex testing was performed on the 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA), a com-
pact microfluidic capillary electrophoresis platform,
using the Agilent DNA 7500 kit (Agilent Technologies).
Before electrophoresis, the PCR products were first
purified using the PureLink PCR kit (Invitrogen), ac-
cording to the kit insert protocol, eluting in 15 L. The
purified PCR product, 3 L, and the 7500 size marker
reagent, 3 L, were then loaded into each of the 12
wells of the bio-analyzer chip. The 31 and 59 repeat
female standard (ATCC CRL-2704D) was run in one
well of each chip so that size determination of samples
near the 55 repeat cutoff could be robustly determined.
The 20 and 200 repeat full-mutation female standard
(Coriell NA 20239) was also run in each chip. Repeat
length results from the unknown samples were interpo-
lated from their initial bp electrophoresis result using a
straight-line standard curve drawn between the four
allele values of these two standards. All blood spot
samples that had been identified by the hybridization




The hybridization assay responses to the panels of refer-
ence samples are shown in Figure 1, A and B, for females
and males, respectively. Both curves are monotonic and
indicate that the assay shows an increasing response to
the number of repeats through the clinical range of inter-
Figure 2. Histogram of the 997 hybridization assay results from female DBS
samples. The individual bin values are scaled on the left axis, and the
cumulative percentage line is scaled on the right axis. Table 1 provides the
corresponding summary results in detail.
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from the shortest normal through the full mutation bound-
ary and then flattens between the 336 and 645 repeat
samples at a normalized ratio of approximately 8. The
male standard curve shows a somewhat higher slope
and a higher maximum normalized ratio of approximately
13. The assay has not yet been fully characterized for its
response to mosaic samples.
The performance of the microfluidic chip electropho-
resis instrument with the PCR products for repeat length
confirmation was also evaluated with the panel of refer-
ence samples. A selection of those results is shown in
Figure 1, C–H. Electrophoresis peaks between the chip
kit’s standards were produced by PCR products from all
of the reference samples. In particular, the results for the
full mutations are as follows: a 650-repeat female stan-
dard (Figure 1G) and a 645-repeat male standard (Figure
1H). Both full-mutation samples produced easily identifi-
able peaks. This demonstrated both the performance of
the proprietary PCR through the wide range of repeat
lengths and the ability of the compact microfluidic instru-
Figure 3. Detailed electropherograms from two reflex tests of DBS samples
using the microfluidic electrophoresis instrument. The assay kit standards at
50 and 10,380 bp bracket the sample peaks in the middle. The electrophero-
gram from the ATCC 31 to 59 reference sample result is overlaid (blue) on
both of the unknown samples (red). A: The long allele of sample 126
confirmed to 53 repeats, just less than the premutation cutoff and visibly59
repeats of the standard. B: The long allele of sample 526 confirmed to 75
repeats, easily visible as59 repeats of the standard. FU, follow-up.ment to detect and confirm full mutations.The bio-analyzer software (Agilent Technologies) and
quantitation of the data to the reference standards sup-
ported the bp sizing of peaks so that repeat numbers
could be assessed within the 1 repeat (or 3 bp) pre-
cision in the normal, intermediate, and premutation range
(100 repeats recommended by the American College
of Medical Genetics guidelines previously referenced).
Female Blood Spot Samples
Hybridization Assay Results
The results of testing 1008 DBS samples from preg-
nant females in the first trimester are summarized numer-
ically in Table 1 and graphically in Figure 2. Of the 1008
samples, 997 produced a result, for a no result rate of
1.1%. This was after a second pass; in the first pass, 43
samples (4.3%) failed to produce a result; these failed
samples were rerun through extraction, PCR, and hybrid-
ization a second time, when 32 of them produced results.
Samples were determined to have produced no result if
the representative fluorescent intensity value of the hy-
bridization assay was 100.
The median value of the hybridization assay results
was 30 repeats and the mode was 28 repeats, which
correlates well with the consensus most prevalent repeat
length of 29.37 The smallest value measured in the sam-
ple set was 17, and the largest value was 83. Seventeen
samples, or 1.7%, were assessed to be 55 repeats,
more than would be expected in a typical population.
Reflex testing needed to include samples with hybridiza-
tion assay results well below the 55 premutation cutoff to
be sure that no true-positive samples would be missed.
Reflex Electrophoresis Results
All samples for which the hybridization assay called
the repeat length 45 were reflex tested by microfluidic
Figure 4. A graphical comparison of selected hybridization assay results
with the corresponding microfluidic electrophoresis reflex testing results.
This includes all of the samples that were tested by electrophoresis: the
samples called as 45 by the hybridization assay plus 29 randomly chosen
samples that were called normal. The dotted line is the theoretical locus
where the results of the hybridization assay and the electrophoresis would be
identical; it is not a regression line fit to the data. Data points from the eight
confirmed premutations (red) and the confirmed intermediates between 45
and 54 repeats (yellow) are shown. Normal data points are shown in blue. By
the preponderance of points laying below the dotted line, the hybridization
assay is shown to overestimate the number of repeats on average in the
intermediate and premutation range.
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trophoresis sizing was performed using PCR products
from characterized reference samples as standards, as
previously described. Figure 3 shows two examples, one
sample with results just above and one with results just
below the premutation cutoff of 55 repeats.
A total of eight premutations of 55 repeats were con-
firmed. At 0.80% or 1 of 125 of the sample set, this is
within the range of the results of other recent studies of
female populations. The shortest hybridization assay re-
sult that produced a confirmed premutation was a 49:
one such sample was confirmed to have 56 repeats. In
addition, 39 samples characterized as normal by the
hybridization assay and chosen at random were reflex
tested by electrophoresis; all of them were confirmed as
normal.
Figure 4 illustrates a graphical comparison between
the hybridization assay results that were45 repeats and
the electrophoresis results. The scatterplot also includes
results from the 39 samples chosen at random that as-
sayed as normal. In the intermediate and above range of
repeats (45), the hybridization assay produces a repeat
result that is slightly larger than that determined by elec-
trophoresis, a desired characteristic in the screening set-
ting at which the avoidance of false-negative results is a
primary concern.
DNA aliquots from the eight confirmed premutation
samples plus the 31 to 59 ATCC reference sample were
sent to an independent clinical laboratory for confirmation
by current standard diagnostic testing (electrophoresis
using a sequencing instrument). All of these samples
were independently confirmed within 1 to 2 repeats.
Discussion
The development of a high-throughput fragile X assay
that produces a fluorescence ratio as the result for each
sample fulfills an unmet need for an assay suitable for
screening. As demonstrated with reference samples, the
hybridization assay produces a robust distinction be-
tween normal and full-mutation samples. Homozygous or
nearly homozygous female normal samples are clearly
differentiated from full mutations by the ratio result. Full
mutations are straightforwardly confirmed as peaks be-
yond a full-mutation boundary standard using the micro-
fluidic electrophoresis reflex test. Therefore, after proper
clinical validation, the prospect of eliminating many
Southern blots from the reflex chain appears to be pos-
sible. In contrast to previously published methods that
require the visual interpretation of complex stutter elec-
tropherograms to make this distinction, these assay re-
sults are numerical values and simple to evaluate at the
laboratory level.
Results for the PCR and hybridization assay are ob-
tained in less time than an 8-hour shift, and the confirma-
tion electrophoresis of screen-positive results takes ap-
proximately an additional 2 hours. All manipulations for
the PCR and hybridization assay are performed in micro-
plates and can be performed with a multichannel pipette
for high throughput, with the prospect for straightforwardautomation. The Luminex 200 suspension array system
reads the fluorescence results of the hybridization assay
unattended. The ratios of fluorescent signals indicative of
the repeat length are simple to calculate and embody into
software, and no visual interpretations of electrophero-
grams are needed for the approximately 95% of samples
that will assay as screen assay negative in most screen-
ing settings.
Reflex electrophoresis performed on the microfluidic
platform has several advantages over electrophoresis on
a sequencing instrument. First, peaks from full-mutation
PCR products are clearly visible and are simple to cate-
gorize as full mutations when run alongside a 200-repeat
reference sample. Full-mutation peaks are difficult to de-
tect in sequencing instruments, especially when set up
primarily for detection of peaks in the normal through
premutation range. Second, the microfluidic system is
much smaller and simpler to maintain than a sequencer.
Finally, both the suspension array and microfluidic sys-
tems together are significantly less expensive invest-
ments than a single capillary sequencer.
This study was performed using DNA from DBS spec-
imens to demonstrate the assay’s performance on the
emerging sample format used for maternal screening.
The level of performance demonstrated herein (4.3% no
results on the first pass and 1.1% no results after retest-
ing the initial no result samples) is appropriate for carrier
screening. The assay standard curves exhibit a signifi-
cant slope through the 200-repeat cutoff for full muta-
tions. These preliminary results suggest that the assay is
a reasonable candidate for screening maternal samples
for premutation yes-no status. With appropriate clinical
validation, this assay will enable high-throughput, low-
cost, low-investment screening.
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